Tirzepatide, under the trade name Mounjaro®, is a first-of-its-kind dual-action GIP/GLP-1 receptor agonist for Type 2 Diabetes (T2D). Approved in 2022, it surpasses conventional GLP-1 receptor agonists in glycemic and weight outcomes. Its promising clinical trial results include reductions in HbA1c, body weight, and mortality, particularly noted in the SURPASS-4 study. With ongoing research into its potential broader benefits, Tirzepatide’s unique pharmacological action offers a groundbreaking alternative in T2D treatment, potentially extending its utility to weight management and metabolic disorders.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Intex Tirze by Intex Pharma, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
